Advanced Bionutritionals GLP-1 Plus
US$ 29.73
surpass-cvot tirzepatide Diabetes Distilled: – demonstrates cardiovascular benefit in secondary prevention SURPASS-CVOT shows tirzepatide delivers comparable
Description
Doses above 15 mg weekly have not been tested in Phase 3
Clinical studies show tirzepatide tablets support weight loss by regulating appetite and boosting metabolism, though results may vary
Key Benefits Technical Details Item Weight Product Dimensions Item model number Item Package Quantity Number of Handles Batteries Required
Tirzepatide, marketed as Zepbound for weight management and Mounjaro for type 2 diabetes, is a dual GIP and GLP-1 receptor agonist
Start with low doses and gradually increase as tolerated, closely monitoring your body's response
Tirzepatide: GI side effects common but well-characterized
